Skin activation by acceleration of pdgf-bb activity

Abstract

This method, which screens drugs that activate the skin, is characterized by causing candidate drugs to act on vascular endothelial cells, and selecting drugs that enhance the expression of PDGF-BB by the cells as a skin activation agent.

1 - 3 . (canceled) 
     
     
         4 . A method for inhibiting skin aging comprising the step of increasing the activity or level of PDGF-BB at a vascular site of the skin, thereby causing mesenchymal stem cells to migrate to endothelial cells whose PDGF-BB activity or level has been increased, so that the mesenchymal stem cells accumulate at the vascular site in which said endothelial cells exist and activate the skin near said vascular site. 
     
     
         5 . A method for screening drugs that activate skin, comprising the steps of
 allowing a candidate drug to act on vascular endothelial cells, and   selecting the drug that accelerates expression of PDGF-BB by the cells for use as a skin activator,   wherein activation of skin is attained by migration of mesenchymal stem cells to the endothelial cells whose PDGF-BB expression level has been increased, thereby causing the mesenchymal stem cells to accumulated at a vascular site in which said endothelial cells exist and activate the skin near said vascular site.   
     
     
         6 . The method according to claim  1 , wherein the selection is carried out by measuring mRNA derived from PDGF-B in the cells by real-time polymerase chain reaction.